Corporate Info Research Reports Consulting News Contact Us
 

 

Free Research Reports

Complete the surveys below to get free findings from each study!

All Current Studies

Market Research

Brand Development & Launch

Clinical Outsourcing Cost Management
   & Decision Making

Consulting Services

Let Cutting Edge Information help you build revenues, reduce costs, and increase efficiency.

Call Jason Richardson at 919-403-6583 today to learn more about our customized research and get a free quote.

 

US Pharmaceutical Launches: Marketing Spend and Structure (PH72)

Purchase E-Copy Now
Download Free Report Summary

Published 2005
18 Brands
221 Pages
500+ Metrics
165 Data Tables and Charts

  Overview

Companies Metrics

Call Oveda Slade at +1-919-403-6583 to get your own copy of "US Pharmaceutical Launches: Marketing Spend and Structure" today.
 
US Pharmaceutical Launches: Marketing Spend and Structure (PH72)
  • Benchmark your brand's marketing resources from early development through post-launch
  • Lobby for additional resources
  • Learn how brands allocated resources to overcome clinical, regulatory, competitive and internal hurdles

The United States continues to offer the pharmaceutical and biotechnology sectors their most lucrative marketplace. Dedicating the right commercial resources for US brand launch -- at the right time -- positions a drug for years of long-term growth.

This is easier acknowledged than accomplished, however.  A brand's resource levels depend upon a mixture of factors: competitive pressures, clinical proficiency, internal hurdles, regulatory challenges, sales expectations and other elements over which US brand teams have limited degrees of control.

United States Pharmaceutical Launches contains US marketing budgets and staffing data for 18 brands. The report's chapters break down brands' spending and headcounts into six time periods and five spending categories:

Time Segments

Spending Categories

 

Brand Activities
This category includes resource allocations associated with basic project and brand management and all that that entails prior to launch. Resources dedicated in this area are allocated to strategic items such as product positioning, pricing (if applicable), health economics, medical affairs, medical publications, managed care and reimbursement, brand and message development, product profile development, packaging, labeling, management of findings from market research and thought leader interactions, the development of promotional strategies, and other strategic branding activities.

Return to the list of spending categories

Market Research
This category includes resource allocations associated with the design and execution of market research and competitive intelligence studies.

Return to the list of spending categories

Thought Leader Development
This category includes all resource allocations associated with thought leader and opinion leader activities, such as advisory boards, KOL meetings and field-based work with national, regional, and local doctors.

Return to the list of spending categories

Advertising
This category includes all resource allocations associated with advertising and promotions, such as formal advertising to physicians, direct-to-consumer advertising, development of conference materials, educational posters, public relations activity, internet activity, and the range of unique promotional tasks that supports every brand.

Note one key exception to this area: advertising here does not include expenditures for sales force operations and support.

Return to the list of spending categories

Sales
This category includes all resource allocations associated with sales force activities dedicated to brand promotion, such as sales force training and deployment, promotional item development, compensation and samples management.

Return to the list of spending categories

Pre-Clinical
The period encompassing pre-clinical testing in laboratory and animal studies to assess safety, biological activity and formulations.  On average, pre-clinical testing lasts more than six years, and it precedes filing with the FDA or other regulatory body for approval to initiate human clinical trials.

Return to the list of time segments

Phase I
The period in which a drug is first tested in healthy human volunteers to determine safety and dosage.

Return to the list of time segments

Phase II
The period of time – usually about two years – when a drug is tested in larger numbers of patients to evaluate effectiveness and look for side effects.

Return to the list of time segments

Phase III
The period encompassing large-scale clinical testing to determine efficacy and safety prior to submission for regulatory approval.

Return to the list of time segments

Registration and Launch
The period beginning with submission for regulatory approval with the FDA and ending with approval for marketing and actual product launch in the United States. 

Return to the list of time segments

First 12-18 Months on market
The period of time immediately following initial launch in the United States that encompasses at least one 12-month cycle

Return to the list of time segments

 

 

CORPORATE INFO RESEARCH REPORTS CONSULTING NEWS CONTACT US HOME
Copyright (c) Cutting Edge Information  p:919-403-6583  Please read our Copyright Policy